In support of this hypothesis, blood drawn from mice in the vaccination study 1 week after inoculation of melphalan-treated melanoma cells showed no significant alterations in T cell populations (data not shown), while the population of intratumoral melanoma-specific CD8+ T cells increased significantly in mice treated with the melphalan-based cell vaccine. Here, CD8A is linked to melanoma.